AVE 25.0% 0.3¢ avecho biotechnology limited

incredible, page-17

  1. 379 Posts.
    Last post, as I've nailed my flag, but Dhukka's fair point merits a, I hope considered, reply.

    No problem with a cap raising. Nice if there had been a thumping upfront - perhaps rather encouraged by all the reports emanating from the company on discussions with all & sundry - but there we go. The concern is simply what it's for & what it can achieve.

    The company's going it alone in a major launch seems unbelievable. The cash usage must be substantial & in any launch would need to be sustained for some time. They carry no serious marketing expertise and a skelton staff.

    The rest to spent on Oxy development will still leave it a long way from completion.

    Looks as if the launch is a last throw for the old regime. I hope the company will give a serious - credible? - explanation of its current reasoning when it announces the funding
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.